HC Wainwright & Co. Maintains Buy on Editas Medicine, Raises Price Target to $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3 to $5.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3 to $5.